Lipocine Inc. (“Lipocine”) (OTCQB/OTCBB: LPCN), a
specialty pharmaceutical company, announced today that Morgan Brown has
joined the Company as Executive Vice President and Chief Financial
Officer (“CFO”). Mr. Brown has more than 20 years of financial and
accounting experience, including over 13 years in financial management
of life science companies.
Most recently, Mr. Brown was the CFO at Innovus Pharmaceuticals, Inc.
(OTCBB: INNV). Previously Mr. Brown was the CFO of World Heart
Corporation (formerly NASDAQ: WHRT) and Lifetree Clinical Research and
the Vice President, Finance and Treasurer of NPS Pharmaceuticals, Inc.
(NASDAQ: NPSP). Before NPS Pharmaceuticals Mr. Brown was a Senior
Manager at KPMG LLP. Mr. Brown is a Certified Public Accountant in Utah,
and he earned a master’s degree in business administration from the
University of Utah and a bachelor’s degree in accounting from Utah State
University.
"We are delighted to welcome Morgan to our executive team. Morgan’s
experience and expertise in the financial management of public life
science companies will be important to us as we grow into a leading
men’s and women’s health company through development and
commercialization of our flagship oral testosterone products," said
Mahesh Patel, President and CEO. “Mr. Brown will also play a key role in
oversight of corporate finance and facilitation of communications with
our investor base and analysts.”
About Lipocine Inc.
Lipocine Inc. is a specialty pharmaceutical company developing
innovative products for use in men’s and women’s health using its
proprietary drug delivery technologies. Lipocine’s lead product
candidate, LPCN 1021, is Phase III ready and is targeted to treat
symptoms of low testosterone for men in need of testosterone replacement
therapy. Additional pipeline candidates include LPCN 1111, a next
generation oral testosterone therapy product, and LPCN 1107, which has
the potential to become the first oral hydroxyprogesterone caproate
product indicated for the prevention of preterm birth.
Forward-Looking Statements
Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995 and include all statements relating to the potential benefits of
Lipocine’s product candidates. Investors are cautioned that all
forward-looking statements involve risk and uncertainties, including
without limitation the risks related to the receipt of regulatory
approvals and other risks detailed in Lipocine's filings with the U.S.
Securities and Exchange Commission, including without limitation its
Current Report on Form 8-K as amended, dated July 24, 2013.
Copyright Business Wire 2013